Currently undergoing clinical trials in Israel and a pilot in Japan, OutSense’s optical IoT device attaches to the toilet bowl. It identifies the optical footprint of feces and urine components and sends the data for AI cloud-based analysis before providing indications of various diseases in real-time.
The device can identify blood in stool, often a sign of colorectal cancer, and can also diagnose and monitor dehydration, urinary tract infections, diarrhea and constipation. Production and commercial sales are planned for Q1 2022.
The OutSense device is meant to replace the manual collection of human waste and its delivery to labs, a procedure which leads many people to defer and delay lifesaving tests.
OutSense works discreetly and continuously and provides automatic alerts, either via a mobile app or to the control screens of medical teams at elderly care facilities and medical institutions.
“The access to real-use environments that the Longevity investment brings to the table is invaluable,” says OutSense CEO Yfat Scialom.
“The ability to partner with a major US healthcare provider serves as a signal to the market that the rules of the game can be changed. It signals that early detection of more diseases through our technology can save huge amounts in healthcare costs, and more importantly save lives.”